Gurjeet Basra
Physician Assistant • Webster, TX
12 Professional Park Dr
Webster, TX 775984127
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on December 10, 2013; this date does not establish years in practice.
-
Published CMS data list 1,107 Original Medicare Part B services in 2020.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020. Published rows only; this is not a quality measure.
-
Published Part B service records, 2020:
- 17003 — Destruction of precancer skin growth, 2-14 growths: 435 service units.
- 99213 — Established patient outpatient office visit: 276 service units.
- 17000 — Destruction of precancer skin growth, 1 growth: 136 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2019 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2020). CPT notice
See all 10 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 842 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Triamcinolone Acetonide — 152 prescription fills, including refills.
- Ketoconazole — 110 prescription fills, including refills.
- Clobetasol Propionate — 99 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 19 records in the table · Guide: How to read Medicare Part D prescriber data
-
More Part D prescriptions than 85% of clinicians listed under Physician Assistant in Webster, TX (2024, 24 clinicians with data). Median for this group: 176. Middle half: 85 to 572.
More Part D prescriptions than 70% of clinicians listed under Physician Assistant in Texas (2024, 4,882 clinicians with data). Median for this group: 261. Middle half: 73 to 938.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 774 in 2017 to 1,107 in 2020.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2017–2020.
Practice Location & Contact Primary Location
12 Professional Park Dr
Webster, TX 775984127
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
What Public CMS Data Show
Physician Assistant: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare-allowed amount
About $46,116 in 2020
The total amount Medicare approved for these services in 2020. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020.
Paid by Medicare
About $32,570 in 2020
The part of the Medicare-allowed amount that Medicare itself paid in 2020, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020.
30-day fills
1,013 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$13,671 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $1,572.86 across 66 records.
By nature of payment
- Food and Beverage: $1,572.86 across 66 records.
Reporting-company totals (3 largest of 14)
- Sanofi and Genzyme US Companies: $338.28 across 10 records.
- Regeneron Pharmaceuticals, Inc.: $270.52 across 10 records.
- Arcutis Biotherapeutics, Inc.: $175.65 across 9 records.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
NPI first issued
2013
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Medicare assignment not listed
CMS data do not show whether this clinician accepts Medicare assignment. This does not mean they do not accept Medicare. Ask the office.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Compared with the same specialty in Webster and Texas
Billing and prescribing volume is not a quality rating.
Medicare Part D prescriptions
More Part D prescriptions than 85% of clinicians listed under Physician Assistant in Webster, TX (2024, 24 clinicians with data). Median for this group: 176. Middle half: 85 to 572.
More Part D prescriptions than 70% of clinicians listed under Physician Assistant in Texas (2024, 4,882 clinicians with data). Median for this group: 261. Middle half: 73 to 938.
Part D drug cost
A higher Part D drug cost than 65% of clinicians listed under Physician Assistant in Webster, TX (2024, 24 clinicians with data). Median for this group: $6,681. Middle half: $743 to $41,995.
Close to the middle for clinicians listed under Physician Assistant in Texas (2024, 4,882 clinicians with data). Median for this group: $7,999. Middle half: $749 to $103,240.
Medicare Part B
Comparisons use 2024 data. The latest CMS data for Gurjeet Basra are from 2020.
54 active clinicians are listed under Physician Assistant with a practice address in Webster, TX (11,008 in Texas).
Addresses are self-reported to NPPES and may be out of date.
Telehealth indicator in Webster
1.9% of these 54 clinicians have the CMS telehealth indicator.
55.6% of these 54 clinicians are listed by CMS as accepting Medicare assignment.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services increased 43% from 774 in 2017 to 1,107 in 2020.
- 2017: 774
- 2018: 1,496
- 2019: 1,549
- 2020: 1,107
-
Medicare-allowed amount
Medicare-allowed amount increased 48% from $31,195 in 2017 to $46,116 in 2020.
- 2017: $31,195
- 2018: $73,413
- 2019: $67,561
- 2020: $46,116
-
Paid by Medicare
Paid by Medicare increased 48% from $22,038 in 2017 to $32,570 in 2020.
- 2017: $22,038
- 2018: $55,202
- 2019: $46,016
- 2020: $32,570
-
Medicare Part D prescriptions
Medicare Part D prescriptions increased 156% from 329 in 2020 to 842 in 2024.
- 2020: 329
- 2021: 88
- 2022: 402
- 2023: 755
- 2024: 842
-
30-day fills
30-day fills increased 201% from 336 in 2020 to 1,013 in 2024.
- 2020: 336
- 2021: 88
- 2022: 482
- 2023: 893
- 2024: 1,013
-
Part D drug cost
Part D drug cost increased 42% from $9,646 in 2020 to $13,671 in 2024.
- 2020: $9,646
- 2021: $1,764
- 2022: $11,887
- 2023: $63,242
- 2024: $13,671
-
Industry payments (Open Payments)
Industry payments (Open Payments) went from $593.21 in 2021 to $1,572.86 in 2025.
- 2021: $593.21
- 2022: $1,507.35
- 2023: $1,542.29
- 2024: $2,275.38
- 2025: $1,572.86
Sources: CMS Medicare Physician & Other Practitioners (2020), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 66 records totaling $1,572.86.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $44.57 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $39.78 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $39.41 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $36.69 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $33.84 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $33.47 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $32.39 |
| Eli Lilly and Company |
Food and Beverage
In-kind items and services
|
TALTZ | General | $31.86 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
Rhapsido | General | $31.14 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $30.99 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $30.89 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $30.23 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $29.22 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $29.07 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $28.83 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $28.72 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $28.65 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $28.58 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $27.69 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
— | General | $26.94 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
— | General | $26.74 |
| Arcutis Biotherapeutics, Inc. |
Food and Beverage
In-kind items and services
|
Zoryve | General | $26.14 |
| Incyte Corporation |
Food and Beverage
Cash or cash equivalent
|
OPZELURA | General | $26.07 |
| Amgen Inc. |
Food and Beverage
In-kind items and services
|
OTEZLA | General | $25.73 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
Rhapsido | General | $25.64 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2019 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2020; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
17003
Destruction of precancer skin growth, 2-14 growths
|
435 | 71 | $7.26 | $5.29 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
276 | 200 | $79.65 | $64.84 |
|
17000
Destruction of precancer skin growth, 1 growth
|
136 | 100 | $72.58 | $41.93 |
|
11102
Biopsy of related skin growth, first growth
|
92 | 77 | $110.68 | $76.18 |
|
17110
Destruction of skin growth, 1-14 growths
|
51 | 45 | $120.32 | $94.44 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
35 | 24 | $120.83 | $95.38 |
|
99212
Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
|
23 | 23 | $54.54 | $39.12 |
|
11103
Biopsy of related skin growth, each additional growth
|
21 | 18 | $57.98 | $47.02 |
|
99203
New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
|
20 | 20 | $127.51 | $94.31 |
|
11300
Shaving of skin growth of body, arms, or legs, 0.5 cm or less
|
18 | 17 | $104.31 | $71.12 |
Source: CMS Part B by Provider and Service, 2020; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Triamcinolone Acetonide | Triamcinolone Acetonide | 152 | 3,764 | $1,034.99 | 122 |
| Ketoconazole | Ketoconazole | 110 | 3,344 | $1,569.76 | 60 |
| Clobetasol Propionate | Clobetasol Propionate | 99 | 2,379 | $4,081.71 | 58 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 2,218 | $529.20 | 31 |
| Mupirocin | Mupirocin | 61 | 969 | $533.25 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 2,430 | $1,051.33 | 34 |
| Hydrocortisone | Hydrocortisone | 52 | 845 | $256.47 | 40 |
| Spironolactone | Spironolactone | 31 | 2,370 | $352.38 | — |
| Valacyclovir | Valacyclovir Hcl | 31 | 619 | $461.05 | 17 |
| Ciclopirox | Ciclopirox | 30 | 1,082 | $546.92 | 13 |
| Clindamycin Phosphate | Clindamycin Phosphate | 26 | 780 | $472.13 | 15 |
| Minocycline Hcl | Minocycline Hcl | 24 | 238 | $119.05 | 23 |
| Prednisone | Prednisone | 19 | 335 | $65.95 | 18 |
| Metronidazole | Metronidazole | 18 | 525 | $831.34 | 13 |
| Fluocinonide | Fluocinonide | 17 | 397 | $583.59 | 13 |
| Gabapentin | Gabapentin | 13 | 570 | $98.07 | — |
| Finasteride | Finasteride | 13 | 810 | $168.55 | — |
| Methotrexate | Methotrexate Sodium | 12 | 282 | $138.78 | — |
| Fluorouracil | Fluorouracil | 12 | 370 | $775.98 | — |
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
NUCC Taxonomy Code: 363A00000X
A physician assistant is a person who has successfully completed an accredited education program for physician assistant, is licensed by the state and is practicing within the scope of that license. Physician assistants are formally trained to perform many of the routine, time-consuming tasks a physician can do. In some states, they may prescribe medications. They take medical histories, perform physical exams, order lab tests and x-rays, and give inoculations. Most states require that they work under the supervision of a physician.
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Dermatology
Doctor of Medicine (M.D.)
Dermatology
Doctor of Medicine (M.D.)
Career & Practice History
NPI enumerated December 10, 2013.
No changes to the name, practice address, taxonomy or NPI status in this record have been observed in the monthly NPPES data files from January 2017 to August 2026.
NPI Administrative Meta
Other Physician Assistants in Webster
- Nikita Patel
- Michelle Hruska, PA-C
- Jordan Brown, PA-C
- Lara Merritt, PA-C
- Sydney Bianco, PA-C
- Amber Cunningham, PA-C
Mailing Address
1799 Fm 528 Rd, Apt 13102
Webster, TX 775984710
Phone: 8326511794